BIOPHARMA CONGRESS IV
November 14, 2018
The Ritz-Carlton, Washington D.C.
1150 22nd Street, NW
DRUG PRICING. APPROVAL STANDARDS. THE FUTURE FDA. PATIENT INPUT.
PRESENTED BY PREVISION POLICY + FRIENDS OF CANCER RESEARCH
Thank you to all that attended! We look forward to seeing you next year. Check our Engaging Innovation blog soon for a full event recap.
In its fourth year, the Biopharma Congress is hosted by Friends of Cancer Research and the team at Prevision Policy, a continuous regulatory and policy information service for biopharma. Each year, the conference addresses and identifies key policy issues on the horizon for the biopharma industry and drives toward dynamic solutions to matters impacting all in the field and the patients they serve. The conference will once again bring together the most innovative leaders from FDA, CMS, industry, advocacy, and Congress, as well as payment and reimbursement organizations for this can’t miss policy event.
HHS DEPUTY SECRETARY ERIC HARGAN
JOSHUA BILENKER (CEO, LOXO ONCOLOGY)
JOE GROGAN (OMB)
DANIEL BEST (HHS)
JOHN O’BRIEN (HHS)
JANET WOODCOCK (CDER)
RICHAR PAZDUR (OCE)
PETER MARKS (CBER)
BOB TEMPLE (CDER)
PETER STEIN (OND)
JAMES SMITH (OND)
AMY MCKEE (OCE)
For more information, please Click HERE.